Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
24.82
-1.23 (-4.74%)
Jan 15, 2026, 1:33 PM EST - Market open
Enliven Therapeutics Employees
Enliven Therapeutics had 62 employees as of December 31, 2024. The number of employees increased by 16 or 34.78% compared to the previous year.
Employees
62
Change (1Y)
16
Growth (1Y)
34.78%
Revenue / Employee
n/a
Profits / Employee
-$1,567,855
Market Cap
1.47B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62 | 16 | 34.78% |
| Dec 31, 2023 | 46 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ELVN News
- 6 days ago - Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars - Benzinga
- 7 days ago - Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones - PRNewsWire
- 8 days ago - Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development - PRNewsWire
- 4 weeks ago - Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - PRNewsWire
- 5 weeks ago - Enliven Therapeutics Announces New CEO to Drive Next Phase of Development - PRNewsWire
- 2 months ago - Enliven Therapeutics: Notable Early Signals, But Too Many Assumptions To Justify A Buy - Seeking Alpha
- 2 months ago - Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PRNewsWire
- 5 months ago - Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting - PRNewsWire